Pancrease MT4
Pancrease MT4, licence 00789445: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Janssen Inc.
- NPN or DIN-HM
- 00789445
- Status
- Inactive licence
- Licence date
- 2 October 2009
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- DIN de transition
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Pancrélipase Source : Extracted from hog pancreata Potency : 4000.0 USP units Lipase | 48.5 mg | Not calculated |
| Pancrélipase Source : Extracted from hog pancreata Potency : 12000.0 USP units Amylase | Not specified | Not calculated |
| Pancrélipase Source : Extracted from hog pancreata Potency : 12000.0 USP units Protease | Not specified | Not calculated |
Non-medicinal ingredients
Gélatine, Microcrystalline cellulose, Stéarate de magnésium, Eau purifiée, Talc, Eudragit L30 D-55, Citrate de triéthyle, Wax, Montan glycol, Silica colloidal anhydrous, Crospovidone, Simethicone emulsion, Opacode black
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | maximum: 2500.0 USP units | Not specified |
| Enfants | minimum: 4.0 Année(s) | maximum: 2500.0 USP units | Not specified |
| Nourrissons | maximum: 12.0 Mois | minimum: 2000.0 USP units ; maximum: 4000.0 USP units | Not specified |
| Enfants | minimum: 1.0 Année(s) ; maximum: 4.0 Année(s) | maximum: 2500.0 USP units | Not specified |
Uses authorised in Canada
Text supplied in English because no French text is available.
For the treatment of steatorrhea secondary to pancreatic insufficiency in disorders such as cystic fibrosis or chronic pancreatitis.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 00789445
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.